Candel Therapeutics advances viral immunotherapies in prostate lung and brain cancer programs

Candel Therapeutics advances viral immunotherapies in prostate lung and brain cancer programs
Candel advances cancer immunotherapies

Candel Therapeutics, Inc. is advancing its pipeline of multimodal viral immunotherapies targeting some of the most challenging cancer types.

The company is focusing on aglatimagene besadenovec for prostate and lung cancer and linoserpaturev for recurrent glioblastoma, highlighting its commitment to develop new options for patients during Cancer Control Month. The initiative underscores the broader trend in oncology of exploring immunotherapy as an innovative method in cancer treatment.

Candel has previously announced plans to present follow-up phase 3 data for CAN-2409 in prostate cancer at the AUA2026 meeting, according to a prior update.Candel Therapeutics, Inc. to present key phase 3 trial follow-up data for CAN-2409 in prostate cancer at AUA2026. The company continues to pursue clinical milestones in its immunotherapy programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.